Magainin Pharm (MAGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN)

MAGN 8.520

-3.3%

Nov 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kech who wrote (172)	4/13/1999 11:11:00 AM
From: Mike McFarland	Read Replies (1) of 233

Magainin and Collaborators Present Data on Squalamine and MSI-1857 At AACR Meeting in Philadelphia biz.yahoo.com Preclinical data presented at the meeting demonstrated squalamine is extremely effective when used alone in the treatment of prostate cancer and when used in combination with platinum based cytotoxic agents in lung cancer. In addition, MSI-1857 demonstrated significant tumor shrinkage when compared to placebo in a breast cancer model. a very good PR, see the link. Hope we see a nice pop...if not, well, I've bought myself another investment if it doesn't do much;-)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next